ArticleCurrent oncology (Toronto, Ont.)2022

Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage.

Yuwen Bao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.